The U.S. Food and Drug Administration (FDA) is reviewing Genentech’s request for Tecentriq (atezolizumab) to be approved, in combination with the chemotherapy Abraxane (nab-paclitaxel), as a first-line treatment for certain triple-negative breast cancer patients. The supplemental Biologics License ... Read more